DRUG vs. IBIO, PPBT, SYBX, VBIV, TCRT, KALA, AYTU, TLPH, GLYC, and GLTO
Should you be buying Bright Minds Biosciences stock or one of its competitors? The main competitors of Bright Minds Biosciences include iBio (IBIO), Purple Biotech (PPBT), Synlogic (SYBX), VBI Vaccines (VBIV), Alaunos Therapeutics (TCRT), KALA BIO (KALA), Aytu BioPharma (AYTU), Talphera (TLPH), GlycoMimetics (GLYC), and Galecto (GLTO). These companies are all part of the "pharmaceutical preparations" industry.
Bright Minds Biosciences (NASDAQ:DRUG) and iBio (NYSE:IBIO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, community ranking, valuation, dividends and media sentiment.
Bright Minds Biosciences has higher earnings, but lower revenue than iBio.
In the previous week, iBio had 5 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 6 mentions for iBio and 1 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 1.92 beat iBio's score of 0.84 indicating that Bright Minds Biosciences is being referred to more favorably in the media.
40.5% of Bright Minds Biosciences shares are owned by institutional investors. Comparatively, 7.9% of iBio shares are owned by institutional investors. 42.7% of Bright Minds Biosciences shares are owned by insiders. Comparatively, 1.1% of iBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Bright Minds Biosciences has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, iBio has a beta of -3.22, indicating that its share price is 422% less volatile than the S&P 500.
iBio received 1 more outperform votes than Bright Minds Biosciences when rated by MarketBeat users.
iBio has a consensus price target of $5.00, indicating a potential upside of 110.08%. Given iBio's higher possible upside, analysts clearly believe iBio is more favorable than Bright Minds Biosciences.
Bright Minds Biosciences' return on equity of -80.64% beat iBio's return on equity.
Summary
Bright Minds Biosciences and iBio tied by winning 6 of the 12 factors compared between the two stocks.
Get Bright Minds Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRUG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRUG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bright Minds Biosciences Competitors List
Related Companies and Tools
